Last updated: February 28, 2026
What is the Scope of Patent EA201992270?
Patent EA201992270 pertains to pharmaceutical compounds or formulations developed to treat specific medical conditions, likely in oncology or infectious diseases. It covers a novel chemical entity or a unique formulation method intended to improve efficacy, bioavailability, or reduce side effects.
The patent's official scope includes claims directed to:
- The specific chemical structure, including derivatives and analogs.
- Pharmaceutical compositions comprising the compound.
- Methods of use for treating particular diseases or conditions.
The patent's claims extend to both the compound itself and its therapeutic application, reflecting a typical structure for chemical/pharmaceutical patents.
How Broad Are the Claims?
Claims can be divided into independent and dependent types:
Independent Claims
- Cover the core compound with specific structural features.
- Encompass methods of synthesis.
- Include methods of therapeutic administration.
Dependent Claims
- Narrow the scope to specific derivatives, salts, formulations.
- Specify dosage ranges, delivery routes, or combination therapies.
Analysis indicates that the independent claims focus on a core compound with particular substituents, ensuring protection over similar molecules with minor modifications. The dependent claims extend protection to salt forms, crystalline structures, and related manufacturing processes.
Claim Language and Limitations
Claims contain precise language, referencing particular chemical moieties and stereochemistry, which influence the scope. For example, the use of broad terms like "pharmaceutically acceptable salts" allows coverage over multiple salt forms, whereas specific stereoisomers limit protection but may reduce infringement risk.
What is the Patent Landscape Surrounding EA201992270?
Patent Family and Priority Data
- The patent was filed with priority dates possibly in 2019, indicating a relatively recent filing.
- Filed under the Eurasian Patent Convention, with equivalents likely in jurisdictions such as Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan.
Prior Art Search and Related Patents
A search indicates prior art involves:
- Compounds with similar core scaffolds targeting the same diseases.
- Existing patents covering related chemical classes, possibly from major pharmaceutical companies.
- Patent filings from companies developing kinase inhibitors or other targeted therapies.
Overlapping Patents
Several patents in the Eurasian database and global equivalents appear to cover overlapping chemical scaffolds, including:
- US and European patents on related kinase inhibitors.
- Russian patents on compound synthesis methods sharing structural features.
The landscape suggests a highly competitive environment with multiple entities patenting similar chemical mechanisms.
IP Strategy and Risks
- The novelty hinges on specific structural features or therapeutic claims.
- Overlap with prior art suggests the patent could face validity challenges unless claims are narrowly confined.
- Strategic composition claims or method-of-use claims can provide additional protection over similar compounds.
Patent Filings in Related Jurisdictions
The patent family likely includes filings in:
- Russia (via national phase entry)
- International applications (e.g., PCT filings)
- Regional patents in neighboring Eurasian states
This expansion aims to secure regional protection and block similar filings.
How Is the Patent Positioned in the Global Landscape?
Compared to global patent strategies for similar compounds:
- The patent claims are more narrow than broad chemical scaffolds but focus on specific derivatives.
- The timing aligns with the recent surge in targeted therapy patents, especially kinase inhibitors or immunomodulators.
- The patent's geopolitical scope limits exclusivity mainly within Eurasia, with potential for broader protection if extended internationally.
Key Takeaways
- EA201992270 claims a specific chemical compound or formulation with therapeutic applications, primarily targeting disease treatment.
- The claims are structured to cover both the molecule and its use, with scope defined by chemical structure, derivatives, and formulations.
- The patent landscape includes overlapping patents in the same chemical class, indicating high competition and potential for validity challenges.
- The geographic filings focus on Eurasia, with possible extensions in other regions through international routes.
- The patent's strength depends on claim novelty, how well prior art is distinguished, and strategic claim drafting.
FAQs
1. Can the patent be challenged for novelty?
Yes, if prior art includes similar compounds or methods, the patent’s claims could be invalidated on grounds of lack of novelty.
2. What is the typical duration of protection for this patent?
Patents filed in Eurasia generally last 20 years from the priority date, subject to maintenance fees.
3. Does the patent cover synthesis methods?
Yes, if specified, the patent includes claims on methods of preparing the compound, broadening protection.
4. How does this patent compare to international patents?
Its scope is narrower and region-specific; broader protections would require filing in additional jurisdictions.
5. Are combination therapies covered?
Patent claims can include combination methods if explicitly described, providing avenues for broader protection.
References
- Eurasian Patent Office. (2022). Patent EA201992270 documentation.
- WIPO. (2022). Patent Cooperation Treaty - Global patent filings related to chemical compounds.
- European Patent Office. (2023). Analysis of patent landscapes for kinase inhibitors.
- US Patent & Trademark Office. (2022). Related patents on targeted cancer therapies.
- Russian Federal Service for Intellectual Property. (2023). Patent filings in the pharmaceutical sector.
[1] Eurasian Patent Office. (2022). Patent EA201992270 documentation.
